Ha Kung Wong

Ha Kung Wong

Venable LLP

Contact
View Bio
RSS

Latest Publications

Share:

First Interchangeable FDA Approval without a Switching Study

Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee® (insulin glargine-yfgn),...more

9/9/2022  /  Biosimilars , Coherus , FDA Approval , Food and Drug Administration (FDA) , Pharmaceutical Industry , Prescription Drugs
26 Results
 / 
View per page
« Previous
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide